瑞非尼治疗转移性胆管癌的特殊疗效:1例报告。

IF 2.3 4区 医学 Q3 ONCOLOGY
Ayberk Bayramgil, Tugce Kubra Gunes, Fatma Gulcicek Ayranci, Duygu Yoruk Atik, Busra Nigdelioglu, Melike Ozcelik, Ozgecan Dulgar Kaya
{"title":"瑞非尼治疗转移性胆管癌的特殊疗效:1例报告。","authors":"Ayberk Bayramgil, Tugce Kubra Gunes, Fatma Gulcicek Ayranci, Duygu Yoruk Atik, Busra Nigdelioglu, Melike Ozcelik, Ozgecan Dulgar Kaya","doi":"10.2174/0115680096378189250422100120","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction/background: </strong>Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases.</p><p><strong>Case presentation: </strong>This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target.</p><p><strong>Conclusion: </strong>This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.\",\"authors\":\"Ayberk Bayramgil, Tugce Kubra Gunes, Fatma Gulcicek Ayranci, Duygu Yoruk Atik, Busra Nigdelioglu, Melike Ozcelik, Ozgecan Dulgar Kaya\",\"doi\":\"10.2174/0115680096378189250422100120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction/background: </strong>Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases.</p><p><strong>Case presentation: </strong>This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target.</p><p><strong>Conclusion: </strong>This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.</p>\",\"PeriodicalId\":10816,\"journal\":{\"name\":\"Current cancer drug targets\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current cancer drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115680096378189250422100120\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096378189250422100120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介/背景:胆管癌(CC)是一种罕见的胆管侵袭性癌症,近几十年来治疗进展有限。CC的5年生存率仍然很低,约为10%,晚期病例甚至更低。病例介绍:本病例报告讨论了一名46岁的转移性CC女性,她使用regorafenib(一种多激酶抑制剂,通常用于其他癌症)获得了显着的无进展生存期。在多线治疗后,瑞非尼作为第7线治疗。尽管最初的不耐受需要减少剂量,但患者获得了22个月的无进展生存期(PFS),病情稳定,某些区域部分消退。她对reorafenib的反应明显超过了文献中的典型结果,其中PFS通常为3至4个月。这种改善可能归因于通过下一代测序鉴定的FGFR2突变,regorafenib可能有效靶向该突变。结论:该病例提示FGFR2突变患者可能受益于瑞非尼,值得进一步研究以探索这种关联,它可以作为一个有希望的靶基因来开发耐药和治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.

Introduction/background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases.

Case presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target.

Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current cancer drug targets
Current cancer drug targets 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
105
审稿时长
1 months
期刊介绍: Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信